CD47 and cancer: Previous work in experimental models of hematologic and solid malignancies have identified CD47 and SIRPα as potential therapeutic targets, whereby blocking this axis (predominantly using anti-CD47 mAb) demonstrated increased phagocytosis of cancer cells by macrophages (2, 4, 5, 126, 128, 134) and M1 polarization (131).